Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3840

Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & Receivers and Integrated insulin pumps), Customer Segments (Diagnostics/Clinic, ICUs and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014 - 2021

LI 15692
Pages: 162
Jun 2015 | 628 Views
face gplus_n
Author's : Debbie Shields
Tables: 27
Charts: 28
twit_n pr_n

The CGM System Market was valued at $418.4 million in 2014 and it is expected to reach $2,930 million by 2021, with a CAGR of 31.3% from 2015 to 2021. The Continuous Glucose Monitoring Systems (CGMS) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. Replacement/repeat sales of components such as sensors drive the growth of the CGMS market. Continuous glucose monitoring finds its application within the patients suffering from hypo and hyperglycemic conditions. 

Key driving factors of continuous glucose monitoring market are the rising incidences of diabetes worldwide, benefits of CGMS devices over POC glucometers, increasing awareness in developing and underdeveloped economies, and focus on developing CGMS devices to serve new end user segment. FDA approval of bionic pancreas would prove to be the major driver of the CGMS market. The CGMS are a more efficient monitoring and treatment alternative for patients with diabetes. 

Prevalence of Type 1 diabetes (ageD <15 years), by Geography
 

Continuous Glucose Monitoring Systems Market by Geography

The CGMS devices have been subject to continuous technological evolution, for instance, smartphone-connected CGMS are the devices that connect with a smartphone’s built-in activity monitor, GPS, scheduling systems, contacts, camera, and voice activation, and sub-sequentially display results and trend analyses. Wearable (also connected with smartphone) CGMS is another prime-target product in the current and immediate future R&D pipeline of ‘wearable’ healthcare devices. Non-invasive CGMs such as Symphony CGM System are gaining importance owing to their user-friendliness, widespread applications and FDA approvals for these products. Bionic pancreas, a smart and a complete diabetes management solution majorly for Type I diabetes patients, is the ultimate objective in terms of technological evolution of the CGMS.

Global Prevalence of Type-2 Diabetes (2000) and Estimated Prevalence (2030)

Global Prevalence Diabetes and Estimated Prevalence
 

The component segment of the CGMS market includes transmitters and receivers, sensors and CGMS compatible insulin pumps. Sensors market contributed for the highest share of revenue in the CGMS market. Sensors market is expected to have the highest growth during the analysis period. Sensors CGMS market will generate the largest market revenue as compared to other CGMS components by 2021. CGM sensors are changed at a very higher frequency as compared to transmitters and receivers due to the limited life. They need to be changed at least once in week, for the proper glucose monitoring in patients body. Due to this limited life, the sensors are purchased in bulk and very frequently by customers. Additionally, the sensors are increasingly used with insulin pumps, which are referred to as an integrated insulin pump. Despite the conversion of existing insulin pump users to CGM users, the CGM manufactures are also collaborating to integrate the newly sold insulin pumps with CGM sensors. The rapid technological advancement in sensors is leading to increased adoption of CGM sensors in diabetes patients. All these factors would eventually lead to an impressive growth of sensors segment in CGMS market.

Based on End-users market analysis, the continuous glucose monitoring market is divided into glucose level testing in diagnostic centers/clinics, ICUs and home healthcare. Among these segments, diagnostics/clinics contributed the highest share of the market revenue. The network of health insurers with the physicians at the Diagnostics/clinics level drives CGMS market in Diagnostics/clinics; also, there are high instances of promotion, usage and deployment of the CGMS products at the Diagnostics/clinics level. However, the CGMS home healthcare market is expected to grow at the highest CAGR. High growth of the home healthcare segment is expected, as home healthcare is economic compared to treatment from healthcare institutions. In addition, home healthcare would be the suitable solution for the geriatric and children population who cannot go to the clinics for the diabetes treatment.

Geographical analysis shows, North America and Europe are the most lucrative market segments in the global CGMs market. High purchasing power that renders increased affordability for CGMS devices are the key factors responsible for the growth of this market in Europe and North America. Asia-Pacific market is expected to grow at a highest CAGR of 48.8% over the analysis period and thus constitutes potential market opportunity for the new market players.

CGMS offers varied benefits over other glucose monitors in monitoring the blood glucose levels of ICU patients. The conventional PoC and SMBG devices impart discomfort or pain in patients. Therefore, CGMS are preferred over SMBG/PoC devices. Undiagnosed’ geriatric patient population would pose as an attractive market opportunity for integrated CGMS developers. Often, the geriatric patients suffer from multiple and chronic diseases that require various medications and at much higher frequency intervals, as compared to the other cohorts. Chances to skip or forget the hypoglycemic medications are higher in geriatric patients. CGMS devices automatically deliver the insulin dosage in such patients without any efforts. Due to these reasons, geriatric patients are more amenable to integrated CGMS devices that help maintain tight glycemic control (TGC) and auto-deliver insulin as per the circadian clock. Over-the-Counter (OTC) customer segment is also the core target market for CGMS devices. Many start-up companies are investing in the development of OTC/Point-of-Care CGMS products, targeting the CGMS products to OTC/POC end user segment such as the non-diabetic population, athletes and other health-conscious population. 

These end-users are more conscious about the minimally invasive and routine health monitoring procedures, which is possible with any of the CGMS product option available in the market. However, a variety of CGMS products is available with different pricing for each of them. If competitive price were affixed for products, the products would become attractive for all economic classes and lead to increase in the uptake of the product. 

The key developed market, namely the United States, follows stringent regulatory (FDA) procedures and guidelines with respect to approval of newer generations of CGMS devices. Commercializing the CGMS devices in the United States is thus challenging, as compared to other regional markets. It has been observed that, gaining European CE approvals is comparatively speedy and easier process than gaining United States FDA approvals. The companies can therefore initially obtain European CE approvals and target emerging markets such as Asia-Pacific and LAMEA CGMS markets.

Key strategies, which are tracked from the recent developments of the CGMS device manufacturing companies/market players include: product launch, collaborations, mergers and acquisitions, expansion and product clearance that include approvals from regulatory authorities such as U.S.FDA, CE marking. Key market players profiled in this report include Medtronic, Dexcom Inc., Animas Corporation, Abbott Diabetic Care (Abbott Laboratories), and others.
 

Continuous Glucose Monitoring (CGM) Systems Market Forecast to 2021

KEY BENEFITS:

  • In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the continuous glucose monitoring systems market.
  • Comprehensive analysis of factors that drive and restrict the growth of the continuous glucose monitoring systems market is provided.
  • The report covers detailed quantitative analysis of the current market, glucose sensing bio-implants and estimations through 2014‐2021, which would enable the stakeholders to capitalize on prevailing market opportunities
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation associated with CGM System market. 
  • An in-depth analysis of current research and clinical developments within CGM System market is provided with key market dynamic factors that help in understanding the behavior of market 
  • Key market players within the glucose meter market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of Monitoring in diabetes management

CGM SYSTEM MARKET KEY SEGMENTS

The CGM System market is segmented based on components, customer segments, end-user demographics and geography (country-level). 

By Components

  • Sensors 

  • Transmitters & Receivers 

  • Integrated insulin pumps 

By Customer Segments

  • Diagnostics/Clinic

  • ICUs

  • Home Healthcare

By End-user Demographics

  • Juveniles

  • Gen X

  • Geriatrics/undiagnosed

By Geography

  • North America 

    • United States

    • Canada

    • Mexico

  • Europe

    • United Kingdom

    • Germany

    • France

    • Others

  • Asia-Pacific

    • China

    • India

    • Australia

    • Others

  • LAMEA

    • Gulf Cooperation Council (GCC)

    • Others

 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Keymarket segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primaryresearch
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 MARKET OVERVIEW

3.1 Marketdefinition
3.2 Need for glucose monitoring systems

3.2.1 Diabetes a pandemic

3.2.1.1 Type 1 diabetes
3.2.1.2 Type-2 diabetes
3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)
3.2.1.4 Gestational Diabetes Mellitus (GDM)
3.2.1.5 Secondary diabetes

3.2.2 Global healthcare expenditure on diabetes

3.3 Emerging technologies in CGMS

3.3.1 Smartphone-connected CGMS
3.3.2 Wearable and smartphone-connected CGMS
3.3.3 Non-invasive CGMS
3.3.4 Invasive CGMS in the R&D pipeline
3.3.5 'Smart diabetes management solution Bionic Pancreas

3.4 CGMS -Prime end user segments

3.4.1 CGMS crucial need in Intensive Care Units (ICUs)

3.4.1.1 Stress Hyperglycemia common occurrence in ICUs
3.4.1.2 Non-standardization and erroneous glycemic control across ICUs

3.4.2 Benefits and factors driving adoption of CGMS in ICUs

3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs
3.4.2.2 Cost benefits from usage of CGMS
3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS
3.4.2.4 CGMS most preferred by ICU staff

3.5 Keyfindings

3.5.1 Top impactingfactors
3.5.2 Top investment pockets

3.5.2.1 CGM Systemmarket By End User Segments
3.5.2.2 CGM Systemmarket by geography

3.5.3 Top winning strategies

3.6 Value chain analysis
3.7 Market share analysis, 2014
3.8 Government regulations
3.9 Reimbursement scenario
3.10 Drivers

3.10.1 Rise in incidence of diabetes globally
3.10.2 Inherent benefits of CGMS over POC glucometers drive market growth
3.10.3 Increase in awareness in developing and underdeveloped economies
3.10.4 Focuson developing OTC/POC CGMS catering to new end user segment - future growth driver
3.10.5 FDA, U.S. approval of Bionic Pancreas future growth driver

3.11 Restraints

3.11.1 Stringent regulatory requirements
3.11.2 Inadequate reimbursements a barrier in CGMS adoption
3.11.3 Accuracy and cost a hindrance in continuing use of CGMS

3.12 Opportunities

3.12.1 Higher adoption rate of CGMS in ICUs
3.12.2 OTC/POC CGMS - expanded product applications/usage
3.12.3 Undiagnosed patient population

3.13 Winning strategies forMNCs for entering emerging markets

3.13.1 Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets
3.13.2 Forming distributionalliances to enhance geographical reach
3.13.3 Raising end-user awareness and competitive product pricing

Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS

4.1 Stand-alone and Integrated CGM systems

4.1.1 Market size and forecast

4.2 Sensors

4.2.1 Key market trends

4.2.1.1 Non-invasive glucose sensors
4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional technology holter-yype retrospective sensors
4.2.1.4 Advanced technology Real-Time sensors

4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Transmitters &Receivers

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Integrated Insulin pumps

4.4.1 Overview
4.4.2 Key market trends
4.4.3 Key growth factors and opportunities
4.4.4 Market size and forecast

Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT

5.1 Market size and forecast
5.2 Diagnostic centers/clinics

5.2.1 Market size and forecast

5.3 ICUs

5.3.1 Market size and forecast

5.4 Home healthcare

5.4.1 Market size and forecast

Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY AGE DEMOGRAPHICS

6.1 Juveniles
6.2 Gen X
6.3 Geriatrics / undiagnosed

Chapter: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY

7.1 North America

7.1.1 Market size and forecast
7.1.2 U.S.
7.1.3 Canada
7.1.4 Mexico

7.2 Europe

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.4 France

7.2.4.1 Key market trends
7.2.4.2 Key growth factors and opportunities

7.2.5 Germany

7.2.5.1 Key market trends
7.2.5.2 Key growth factors and opportunities

7.2.6U.K.

7.2.6.1 Key market trends
7.2.6.2 Key growth factors and opportunities

7.2.7 Other European countries

7.3 Asia-Pacific

7.3.1 Market size and forecast
7.3.2 India

7.3.2.1 Key market trends

7.3.3 Australia

7.3.3.1 Key market trends

7.3.4 China

7.3.4.1 Key market trends

7.3.5 Other APAC countries

7.4 LAMEA

7.4.1 Overview
7.4.2Market size and forecast
7.4.3 Gulf Cooperation Council (GCC)

7.4.3.1 Key market trends

Chapter: 8 COMPANY PROFILES

8.1 Medtronic Plc.

8.1.1 Company overview
8.1.2 Business performance
8.1.3 Strategic moves and developments

8.1.3.1 Principal strategies: product launch
8.1.3.2 Secondary strategies: approval
8.1.3.3 Other strategies: strategic alliance and collaboration

8.1.4 SWOT analysis of Medtronic Plc

8.2 Dexcom Inc.

8.2.1 Company overview
8.2.2 Business performance
8.2.3 Strategic moves and developments

8.2.3.1 Principal strategies: agreement/partnership
8.2.3.2 Secondary strategies: approval
8.2.3.3 Other strategies: acquisition

8.2.4 SWOT analysis of Dexcom

8.3 Abbott Diabetic Care (Abbott Laboratories)

8.3.1 Company overview
8.3.2 Business performance
8.3.3 Strategic moves and developments
8.3.4 SWOT analysis of Abbott diabetic care

8.4 Animas Corporation

8.4.1 Company overview
8.4.2 Strategic moves and developments
8.4.3 SWOT analysis of Animas Corporation

8.5 Echo Therapeutics

8.5.1 Company Overview
8.5.2 Strategic moves and development
8.5.3 SWOT Analysis of Echo Therapeutics

8.6 Insulet Corporation

8.6.1 Company overview
8.6.2 Strategic moves and developments
8.6.3 SWOT analysis of INSULET Corporation

8.7 Glysens Inc.

8.7.1 Company overview
8.7.2 Strategicmoves and developments
8.7.3 SWOT Analysis of Glysens Inc.

8.8 Senseonics, Inc.

8.8.1 Company overview
8.8.2 Strategic moves and development
8.8.3 SWOT analysis of Senseonics, Inc.

LIST OF FIGURES

FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20 79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGM SYSTEMMARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGM
SYSTEM MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGM
SYSTEMMARKET BY YEAR, 2010 2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGM
SYSTEMMARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)
FIG. 16 GLOBAL CGM
SYSTEMMARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.

LIST OF TABLE

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
TABLE 3 GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 4 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014 2021 ($MILLION)
TABLE 5 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 6 GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
TABLE 8 GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 9 GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 10 GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 11 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 12 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
TABLE 13 GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 14 NORTH AMERICA CGM
SYSTEMMARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 15 NORTH AMERICA CGM
SYSTEMMARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 18 EUROPE CGM
SYSTEMMARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 19 TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
TABLE 20 PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
TABLE 21 APAC CGM
SYSTEM MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 22 APAC CGM
SYSTEMMARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 23 MEDICAL DEVICES USED IN AUSTRALIA
TABLE 24 LAMEA CGM
SYSTEMMARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 25 LAMEA CGM
SYSTEMMARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 26 MEDTRONIC BUSINESS SNAPSHOT
TABLE 27 MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
TABLE 28 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 29 ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
TABLE 30 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 31 ECHO THERAPEUTICS COMPANY SNAPSHOT
TABLE 32 INSULET CORPORATION BUSINESS SNAPSHOT
TABLE 33 GLYSENS INC. BUSINESS SNAPSHOT
TABLE 34 SENSEONICS, INC. SNAPSHOT

 
 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, Please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts